Title: Prognostic Implications of CK19 Positivity in Patients with Early
Recurrent Hepatocellular Carcinoma after Hepatic Resection Undergoing Transarterial
Chemoembolization
Version: 1 Date: 03 Apr 2024
Reviewer's report:
Review of the manuscript entitled “Prognostic Implications of CK19 Positivity in Patients with
Early Recurrent Hepatocellular Carcinoma after Hepatic Resection Undergoing Transarterial
Chemoembolization”
It has been reported that CK19-high expressing hepatocellular carcinoma has a poor prognosis.
The author reports on CK19 expression and prognosis after TACE treatment in early recurrence.
The authors state that they are investigating the expression of CK19 and the therapeutic effect
of TACE, but since there is no description of the type of recurrence, I believe that they are
merely showing the relationship between CK19 expression and the prognosis of hepatocellular
carcinoma.
1. Please describe the reason for setting the cutoff for CK19 at 5%.
2.Please create a histogram of CK19 using figure.
3. Surgical specimens are stained for CK19, and although it has been reported that CK19 is
associated with prognosis, why was CK19 not associated with the period until postoperative
recurrence?
4. The authors indicate PFS, but does PFS only mean recurrence in the TACE treatment area? If
extrahepatic and intrahepatic recurrence in areas other than the treated area is included in PFS,
it may not be a result of the relationship between CK19 and TACE treatment effects, but rather
a relationship between CK19 and prognosis. The recurrence format should also be stated.
Title: Prognostic Implications of CK19 Positivity in Patients with Early
Recurrent Hepatocellular Carcinoma after Hepatic Resection Undergoing Transarterial
Chemoembolization
Version: 1 Date: 03 Apr 2024
Reviewer's report:
Review of the manuscript entitled “Prognostic Implications of CK19 Positivity in Patients with
Early Recurrent Hepatocellular Carcinoma after Hepatic Resection Undergoing Transarterial
Chemoembolization”
It has been reported that CK19-high expressing hepatocellular carcinoma has a poor prognosis.
The author reports on CK19 expression and prognosis after TACE treatment in early recurrence.
The authors state that they are investigating the expression of CK19 and the therapeutic effect
of TACE, but since there is no description of the type of recurrence, I believe that they are
merely showing the relationship between CK19 expression and the prognosis of hepatocellular
carcinoma.
1. Please describe the reason for setting the cutoff for CK19 at 5%.
2.Please create a histogram of CK19 using figure.
3. Surgical specimens are stained for CK19, and although it has been reported that CK19 is
associated with prognosis, why was CK19 not associated with the period until postoperative
recurrence?
4. The authors indicate PFS, but does PFS only mean recurrence in the TACE treatment area? If
extrahepatic and intrahepatic recurrence in areas other than the treated area is included in PFS,
it may not be a result of the relationship between CK19 and TACE treatment effects, but rather
a relationship between CK19 and prognosis. The recurrence format should also be stated.
Please review this paper.
user
Title: Prognostic Implications of CK19 Positivity in Patients with Early
Recurrent Hepatocellular Carcinoma after Hepatic Resection Undergoing Transarterial
Chemoembolization
Version: 1 Date: 03 Apr 2024
Reviewer's report:
Review of the manuscript entitled “Prognostic Implications of CK19 Positivity in Patients with
Early Recurrent Hepatocellular Carcinoma after Hepatic Resection Undergoing Transarterial
Chemoembolization”
It has been reported that CK19-high expressing hepatocellular carcinoma has a poor prognosis.
The author reports on CK19 expression and prognosis after TACE treatment in early recurrence.
The authors state that they are investigating the expression of CK19 and the therapeutic effect
of TACE, but since there is no description of the type of recurrence, I believe that they are
merely showing the relationship between CK19 expression and the prognosis of hepatocellular
carcinoma.
1. Please describe the reason for setting the cutoff for CK19 at 5%.
2.Please create a histogram of CK19 using figure.
3. Surgical specimens are stained for CK19, and although it has been reported that CK19 is
associated with prognosis, why was CK19 not associated with the period until postoperative
recurrence?
4. The authors indicate PFS, but does PFS only mean recurrence in the TACE treatment area? If
extrahepatic and intrahepatic recurrence in areas other than the treated area is included in PFS,
it may not be a result of the relationship between CK19 and TACE treatment effects, but rather
a relationship between CK19 and prognosis. The recurrence format should also be stated.
assistant